UnitedHealth Group has remained a subject of active institutional attention heading into mid-2026. The company operates across managed care, pharmacy benefits, and health services segments, and continues to draw scrutiny amid a broader environment of elevated healthcare costs and regulatory developments. A prior briefing published on 2026-05-24 noted these dynamics as ongoing areas of focus for market participants [Brief - 2026-05-24].
For the trailing twelve months ending 2026-03-31, UnitedHealth Group reported revenue of approximately $449.7 billion, reflecting year-over-year growth of 1.96%. Net income over the same period was $12.8 billion, producing a net margin of 2.85% and an operating margin of 4.19%. Earnings per share grew 0.73% year-over-year. The company held $28.0 billion in cash against $77.9 billion in total debt. The reported P/E ratio stood at 28.64, with a market capitalisation of approximately $345.3 billion [SEC 10-Q - UNH - 2026-03-31].
Institutional ownership shifts were material in the most recent reporting period. Millennium Management added 56% to its UNH position, while AQR Capital increased its holding by 36%, and Soros Fund Management expanded its position by 14% [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Soros Fund Mgmt - Q1 2026]. Conversely, Citadel reduced its position by 19% and Tiger Global trimmed its holding by 17% [SEC 13F - Citadel - Q1 2026] [SEC 13F - Tiger Global - Q1 2026]. These diverging moves across major institutional filers were the primary trigger for this report.
The prevailing macroeconomic backdrop features a 10-year Treasury yield of 4.45% and a 2-year yield of 3.99%, producing a normal yield curve with a spread of 46 basis points [FRED DGS10] [FRED DGS2]. This rate environment represents the broader fixed-income context within which large-cap healthcare equities such as UNH are currently operating.